Article
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
Antiviral therapy - 1 Jan 2011
Vallet Sophie, Viron Florent, Henquell Cecile, Le Guillou-Guillemette Helene, Lagathu Giséle, Abravanel Florence, Trimoulet Pascale, Soussan Patrick, Schvoerer Evelyne, Rosenberg Arielle, Gouriou Stephanie, Colson Philippe, Izopet Jacques, Payan Christopher
Abstract excerpt
BACKGROUND: Resistant HCV populations may pre-exist in patients before NS3 protease inhibitor therapy and would likely be selected under specific antiviral pressure. The higher prevalence and lower rate of response to treatment associated with HCV genotype 1 infections has led to drug discovery efforts being focused primarily on enzymes produced by this genotype. Protease inhibitors may also be useful for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.